TBXT and chordoma: The EGFR inhibitor afatinib, which we included as a positive control because it down-regulates TBXT (14, 16), was equally harmful to chordoma cells but, as expected, not to the TBXT-negative and EGFR-inactive U2OS cells (Fig. 6C).